From Human Brain
to Global Consciousness

Will We Extend
the Human Lifespan?

Where Are the
New Therapeutics?

Are We the
Next Frontier?

Visionary Game Changer

Who Are We?

Signum Biosciences

In 2004, Stock rolled up his sleeves to focus on the unmet medical need of Alzheimer's. He co-founded Signum Biosciences to exploit a breakthrough in the global regulation of cell-signaling pathways made by his brother, Dr. Jeffry Stock, a professor of Molecular Biology at Princeton University, a world authority in Signal Transduction.

Signum is an innovative biotechnology company developing a new class of therapeutics called Signal Transduction Modulators or STMs. These have numerous therapeutic applications, including Alzheimer's, Parkinson's and various inflammatory skin diseases. Signum is now working actively with one of its partners, GlaxoSmithKline, to develop a therapeutic STM for Alzheimer's, and through its subsidiary Nutralogix is developing a cognitive protective/enhancer as a neutraceutical that can be broadly available at a lower cost. The company's second subsidiary, Argyle Therapeutics, has partnered with Elizabeth Arden in the US and Rohto Pharmaceuticals in Japan to sell anti-inflammatory and anti-Rosacea skincare products.

If the business model and scientific approach being pioneered at Signum prove successful, this could have major consequences for multiple diseases of aging, because chronic inflammation and dysregulation of signal transduction play so significant role in many of them. Gregory, who has an MBA from Harvard Business School, served as the founding CEO of Signum until 2010 and continues to serve on the company's Board of Directors.

Napo Pharmaceuticals

Since, 2008, Stock has been active on the board of Napo Pharmaceuticals, as Crofelemer, the company's breakthrough therapeutic for diarrhea, the second most prevalent cause of childhood mortality, worked its way through phase 2 and phase 3 clinical trials. This drug, Fulyzag, a natural product derived from the latex of the Croton lechleri tree in the Amazon Basin received FDA approval in late 2012 as a botanical drug for diarrhea associated with antiretroviral therapy treatment of HIV.